disconnect at any time.
—
S1: Financial and operational highlights:
– Revenue: $2,770,000,000 for the first quarter, representing 3% growth versus Q1 2024.
– Segments: Significant revenue from cystic fibrosis medications and new products like Gernavix and AlifTrac.
– Gross margins and revenue growth rate not provided in specific numerical values.
– Cash reserve amount: $11,400,000,000 in cash and investments.
– R&D and marketing expenses: $1,230,000,000 combined non-GAAP R&D, acquired IPR&D, and SG&A expenses.
– Total sales in relevant units or growth rate: Gernavix showed 20,000 prescriptions filled by April. Gatheriv momentum in cell collections and patient treatments for Kashyvi.
S2: Market Expansion
– Expansion into Europe, the UK, and Australia for CF medications; expanding patient eligibility with new labels.
S3: Strategic Cooperation
– Agreement with the FDA to advance Povatacept to pivotal development in primary membranous nephropathy; planned subcutaneous autoinjector.
S4: New Product Launch
– AlifTrex for cystic fibrosis and Gernavix for moderate to severe acute pain launched in the U.S.
– Continuing global launch of Kashyvi for sickle cell disease and beta thalassemia.
S5: Management change
– Stuart Arbuckle retiring as Chief Operating Officer, Duncan McKechnie to become Chief Commercial Officer effective July 1.
S6: Next quarter forward-looking estimates by the management team
– Revised 2025 total revenue guidance increased to a range of $11,850,000,000 to $12,000,000,000.
– Continued focus on broadening payer coverage for Gernavix and advancing pivotal studies for several pipeline products.
– Anticipate filing for regulatory submissions in 2026 for several therapies pending trial results.